GlassScriptPhysician profile
Eric S Thomsen
NPI 1659374437
$3,386.47
in general payments reported to CMS, 2019-2025
26 companies · $80.95 in 2025
The $80.95 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $167 · 2021: $636 · 2022: $771 · 2023: $558 · 2024: $450 · 2025: $80.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $585.30 | 2021-2024 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.98 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $297.05 | 2019-2024 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $277.89 | 2021-2022 | |
| Pfizer INC. | $255.75 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $210.21 | 2022 | |
| Lilly USA, LLC | $204.31 | 2019-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $167.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $166.76 | 2019-2023 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $157.75 | 2021-2024 | Xarelto |
| Genzyme Corporation | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $93.76 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $91.30 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $90.20 | 2019-2021 | |
| Allergan, INC. | $73.62 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $59.53 | 2020-2024 | Vaxneuvance, Gardasil, Gardasil 9 |
| Boston Scientific Corporation | $23.54 | 2019 | |
| Astellas Pharma US INC | $23.22 | 2023 | Veozah |
| Abbott Laboratories | $22.09 | 2024 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $18.51 | 2022 | |
| Daiichi Sankyo INC. | $15.91 | 2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $14.58 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $14.23 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.49 | 2023 | Xifaxan |
| Glaxosmithkline, LLC. | $12.88 | 2022 | |
| Dexcom, INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Thomsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.